Robert B Livingston, MD
Affiliations: | University of Washington, Seattle, Seattle, WA |
Google:
"Robert Livingston"Bio:
https://deptmedicine.arizona.edu/news/2016/lifelong-cancer-fighter-dr-robert-livingston-passes-away
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Woodward WA, Barlow WE, Jagsi R, et al. (2020) Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. Jama Oncology |
| Gralow JR, Barlow WE, Paterson AHG, et al. (2019) Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. Journal of the National Cancer Institute |
| Segar JM, Reed D, Stopeck A, et al. (2019) A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer. The Oncologist |
| Mehta RS, Barlow WE, Albain KS, et al. (2019) Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. The New England Journal of Medicine. 380: 1226-1234 |
| Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, et al. (2018) Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenetics and Genomics. 28: 49-55 |
| Mehta R, Barlow W, Albain K, et al. (2018) Abstract PD5-07: A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226 Cancer Research. 78 |
| Budd GT, Barlow WE, Moore HCF, et al. (2017) SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy. Journal of Clinical Oncology. 35: 521-521 |
| Pelekanou V, Barlow WE, Wahlde Mv, et al. (2017) Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. Journal of Clinical Oncology. 35: 519-519 |
| Potkul RK, Unger JM, Livingston RB, et al. (2016) Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. Npj Breast Cancer. 2: 16024 |
| Woodward WA, Barlow WE, Jagsi R, et al. (2016) The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814. International Journal of Radiation Oncology, Biology, Physics. 96: S146 |